Go to
JCI Insight
Citations to this article
Eric G. Meissner, … , Anthony S. Fauci, Shyamasundaran Kottilil
Published July 1, 2014
Citation Information: J Clin Invest. 2014;124(8):3352-3363. https://doi.org/10.1172/JCI75938.
Citation Information: J Clin Invest. 2014;124(8):3352-3363. https://doi.org/10.1172/JCI75938.
Abstract
Authors
Eric G. Meissner, David Wu, Anu Osinusi, Dimitra Bon, Kimmo Virtaneva, Dan Sturdevant, Steve Porcella, Honghui Wang, Eva Herrmann, John McHutchison, Anthony F. Suffredini, Michael Polis, Stephen Hewitt, Ludmila Prokunina-Olsson, Henry Masur, Anthony S. Fauci, Shyamasundaran Kottilil
Total citations by year
Citation information
Citations to this article (112)
| Title and authors | Publication | Year |
|---|---|---|
|
Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment‐Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab
Watanabe N, Kobayashi T, Iwaki M, Nogami A, Wada N, Shimizu A, Komori T, Koike H, Sahashi Y, Nakajima A, Yoneda M |
JGH Open: An Open Access Journal of Gastroenterology and Hepatology | 2025 |
|
Persistence of hepatitis C virus in peripheral blood mononuclear cells of patients who achieved sustained virological response following treatment with direct-acting antivirals is associated with a distinct pre-existing immune exhaustion status
Osuch S, Kazek M, Emmel P, Berak H, Radkowski M, Cortés-Fendorf K |
Scientific Reports | 2025 |
|
Evaluation of patients treated with direct-acting anti-viral therapy for chronic hepatitis C and their risk of hepatocellular carcinoma in Hong Kong.
Chow VYS, Cheung WI |
BMC Gastroenterology | 2024 |
|
Assessment of ubiquitin specific Peptidase-18 gene in peripheral blood of chronic hepatitis C patients treated with direct-acting antiviral drugs
Ullah S, Naveed M, Ali A, Bibi S, Idrees W, Rafique S, Idrees M, Waqas M, Uddin J, Jan A, Khan A, Al-Harrasi A |
Heliyon | 2024 |
|
Impact of Treatment with Direct Antivirals on Coagulation Parameters in Patients with Hepatitis C Virus-Related Liver Cirrhosis and Sustained Virological Response
Huiban L, Stanciu C, Muzica CM, Girleanu I, Avram R, Damian I, Nastasa R, Stratina E, Zenovia S, Minea H, Stafie R, Rotaru A, Singeap AM, Chiriac S, Balmus IM, Trifan A |
Medicina | 2024 |
|
Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?
Smirne C, Crobu MG, Landi I, Vercellino N, Apostolo D, Pinato DJ, Vincenzi F, Minisini R, Tonello S, D\u2019Onghia D, Ottobrelli A, Martini S, Bracco C, Fenoglio LM, Campanini M, Berton AM, Ciancio A, Pirisi M |
Viruses | 2024 |
|
Hepatitis D infection induces IFN-β-mediated NK cell activation and TRAIL-dependent cytotoxicity
Christopher Groth, Jovana Maric, Irene G Lázaro, Tomáš Hofman, Zhenfeng Zhang, Yi Ni, Franziska Keller, Maike Hofmann, Christoph Neumann-Haefelin, Carsten Sticht, Karsten Rippe, Stephan Urban, Adelheid Cerwenka |
Frontiers in immunology | 2023 |
|
CD4/CD8 Ratio could be predictor of burden hepatocellular carcinoma in Egyptian chronic hepatitis C after combined sofosbuvir and daclatasvir therapy.
El Menshawy N, Hassan N, Khariza M, AlAshery H, Baghat M, Ashour R |
African health sciences | 2023 |
|
In HIV-Infected Immunological Non-Responders, Hepatitis C Virus Eradication Contributes to Incomplete Normalization of Systemic Inflammation Indexes, but Does Not Lead to Rapid CD4+ T-Cell Count Recovery.
Saidakova EV, Korolevskaya LB, Shmagel NG, Vlasova VV, Shardina KY, Chereshnev VA, Shmagel KV |
Doklady Biochemistry and Biophysics | 2023 |
|
DAA-mediated HCV cure reduces HIV DNA levels in HCV/HIV coinfected people
Gobran ST, Pagliuzza A, Khedr O, Fert A, Chomont N, Bruneau J, Klein MB, Ancuta P, Shoukry NH |
Journal of virology | 2023 |
|
Single-cell atlas of the liver myeloid compartment before and after cure of chronic viral hepatitis
Cui A, Li B, Wallace MS, Gonye AL, Oetheimer C, Patel H, Tonnerre P, Holmes JA, Lieb D, Yao BS, Ma A, Roberts K, Damasio M, Chen JH, Piou D, Carlton-Smith C, Brown J, Mylvaganam R, Fung JM, Sade-Feldman M, Aneja J, Gustafson J, Epstein ET, Salloum S, Brisac C, Thabet A, Kim AY, Lauer GM, Hacohen N, Chung RT, Alatrakchi N |
Journal of hepatology | 2023 |
|
Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication
M Lu, M Yeh, C Huang, S Wang, Y Tsai, P Tsai, Y Ko, C Lin, K Chen, Y Wei, P Hsu, C Hsu, T Jang, T Liu, P Liang, M Hsieh, Z Lin, S Chen, C Huang, J Huang, C Dai, W Chuang, M Yu |
World journal of gastroenterology : WJG | 2022 |
|
Response of Human Liver Tissue to Innate Immune Stimuli
X Wu, J Roberto, A Knupp, A Greninger, C Truong, N Hollingshead, H Kenerson, M Tuefferd, A Chen, D Koelle, H Horton, K Jerome, S Polyak, R Yeung, I Crispe |
Frontiers in immunology | 2022 |
|
Immunological Characteristics of Patients Receiving Ultra-Short Treatment for Chronic Hepatitis C
Madsen LW, Christensen PB, Øvrehus A, Bryde DM, Holm DK, Lillevang ST, Nielsen C |
Frontiers in Cellular and Infection Microbiology | 2022 |
|
The Impact of Direct-Acting Antiviral Agents on Cytomegalovirus Reactivation in Chronic Hepatitis C Infection.
Dawood RM, Gomaa AA, Abd El Meguid M, Hassan EA, Salum GM, Fares HM, El Awady MK, Fares EM, Esmat G |
Asian Pacific Journal of Cancer Prevention | 2022 |
|
No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapy
Korenaga M, Murata K, Izumi N, Tamaki N, Yokosuka O, Takehara T, Sakamoto N, Suda G, Nishiguchi S, Enomoto H, Ikeda F, Yanase M, Toyoda H, Genda T, Umemura T, Yatsuhashi H, Yamasaki K, Ide T, Toda N, Kanda T, Nirei K, Ueno Y, Haga H, Nishigaki Y, Nakane K, Omata M, Mochizuki H, Aoki Y, Imamura M, Kanto T, Mizokami M |
2022 | |
|
Downregulation of SOCS1 increases interferon-induced ISGylation during differentiation of induced-pluripotent stem cells to hepatocytes.
Edwards JS, Delabat SA, Badilla AD, DiCaprio RC, Hyun J, Burgess RA, Silva T, Dykxhoorn DM, Chen SX, Wang L, Ishida Y, Saito T, Thomas E |
2022 | |
|
Unraveling the Molecular Mechanisms Involved in HCV-Induced Carcinogenesis
Heredia-Torres TG, Rincón-Sánchez AR, Lozano-Sepúlveda SA, Galan-Huerta K, Arellanos-Soto D, García-Hernández M, Garza-Juarez AD, Rivas-Estilla AM |
Viruses | 2022 |
|
Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR.
Nakagawa M, Asahina Y, Kakinuma S, Okamoto R |
Journal of Gastroenterology | 2022 |
|
Liver Abnormalities after Elimination of HCV Infection: Persistent Epigenetic and Immunological Perturbations Post-Cure
SJ Polyak, IN Crispe, TF Baumert |
Pathogens | 2021 |
|
Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection
PS Sung, EC Shin |
Journal of Clinical Medicine | 2021 |
|
Single-cell transcriptomic analyses of T cells in chronic HCV-infected patients dominated by DAA-induced interferon signaling changes
MA Burchill, MP Salomon, L Golden-Mason, A Wieland, AC Maretti-Mira, M Gale, HR Rosen, AJ Zajac |
PLoS pathogens | 2021 |
|
A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection
ST Gobran, P Ancuta, NH Shoukry |
Frontiers in immunology | 2021 |
|
Occult Infection with Hepatitis C Virus: Looking for Clear-Cut Boundaries and Methodological Consensus
A Wróblewska, KP Bielawski, K Sikorska |
Journal of Clinical Medicine | 2021 |
|
Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination
CJ Angel, EA Pham, H Du, F Vallania, BJ Fram, K Perez, T Nguyen, Y Rosenberg-Hasson, A Ahmed, CL Dekker, PM Grant, P Khatri, HT Maecker, JS Glenn, MM Davis, D Furman |
Proceedings of the National Academy of Sciences | 2021 |
|
Hepatitis C virus treatment with direct‐acting antivirals induces rapid changes in the hepatic proteome
LE Ball, B Agana, S ComteWalters, DC Rockey, H Masur, S Kottilil, EG Meissner |
Journal of Viral Hepatitis | 2021 |
|
Hepatitis C Virus Relapse After Ultrashort Direct-Acting Antiviral Therapy Associates With Expression of Genes Involved With Natural Killer-Cell and CD8+ T-Cell Function
C Orr, H Masur, S Kottilil, EG Meissner |
Open Forum Infectious Diseases | 2021 |
|
Associations between Psychosocial Factors and Circulating Cytokines in Breast Cancer Survivors
Leschak CJ, Dutcher JM, Haltom KE, Breen EC, Bower JE, Eisenberger NI |
Psychology & Health | 2021 |
|
Follicular T helper cells shape the HCV-specific CD4 T cell repertoire after viral elimination
Maike Smits, Katharina Zoldan, Naveed Ishaque, Zuguang Gu, Katharina Jechow, Dominik Wieland, Christian Conrad, Roland Eils, Catherine Fauvelle, Thomas Baumert, Florian Emmerich, Bertram Bengsch, Christoph Neumann-Haefelin, Maike Hofmann, Robert Thimme, Tobias Boettler |
Journal of Clinical Investigation | 2020 |
|
Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection
Xiaoming Cheng, Takuro Uchida, Yuchen Xia, Regina Umarova, Chun-Jen Liu, Pei-Jer Chen, Anuj Gaggar, Vithika Suri, Marcus Maximilian Mücke, Johannes Vermehren, Stefan Zeuzem, Yuji Teraoka, Mitsutaka Osawa, Hiroshi Aikata, Keiji Tsuji, Nami Mori, Shuhei Hige, Yoshiyasu Karino, Michio Imamura, Kazuaki Chayama, T. Jake Liang |
Journal of Clinical Investigation | 2020 |
|
Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy
A Balagopal, LM Smeaton, J Quinn, CS Venuto, GD Morse, V Vu, B Alston-Smith, DE Cohen, JL Santana-Bagur, DD Anthony, MS Sulkowski, DL Wyles, AH Talal |
The Journal of Infectious Diseases | 2020 |
|
Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment S Dash, Y Aydin, KE Widmer, L Nayak |
Journal of Hepatocellular Carcinoma | 2020 |
|
Cirrhosis Hampers Early and Rapid Normalization of Natural Killer Cell Phenotype and Function in Hepatitis C Patients Undergoing Interferon-Free Therapy
E Perpiñán, S Pérez-Del-Pulgar, MC Londoño, Z Mariño, C Bartres, P González, M García-López, E Pose, S Lens, MK Maini, X Forns, G Koutsoudakis |
Frontiers in immunology | 2020 |
|
Interferon Response in Hepatitis C Virus-Infected Hepatocytes: Issues to Consider in the Era of Direct-Acting Antivirals
PS Sung, EC Shin |
International journal of molecular sciences | 2020 |
|
Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics
L Rinaldi, R Nevola, G Franci, A Perrella, G Corvino, A Marrone, M Berretta, MV Morone, M Galdiero, M Giordano, LE Adinolfi, FC Sasso |
Cancers | 2020 |
|
Hepatitis C Virus (HCV) Clearance After Treatment With Direct-Acting Antivirals in Human Immunodeficiency Virus (HIV)-HCV Coinfection Modulates Systemic Immune Activation and HIV Transcription on Antiretroviral Therapy
Y Ghiglione, ML Polo, A Urioste, A Rhodes, A Czernikier, C Trifone, MF Quiroga, A Sisto, P Patterson, H Salomón, MJ Rolón, S Bakkour, SR Lewin, G Turk, N Laufer |
Open Forum Infectious Diseases | 2020 |
|
Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis
WR Treem, M Palmer, I Lonjon-Domanec, D Seekins, L Dimick-Santos, MI Avigan, JF Marcinak, A Dash, A Regev, E Maller, M Patwardhan, JH Lewis, DC Rockey, AM Bisceglie, JW Freston, RJ Andrade, N Chalasani |
Drug Safety | 2020 |
|
Sofosbuvir Activates EGFR-Dependent Pathways in Hepatoma Cells with Implications for Liver-Related Pathological Processes
D Bojkova, S Westhaus, R Costa, L Timmer, N Funkenberg, M Korencak, H Streeck, F Vondran, R Broering, S Heinrichs, KS Lang, S Ciesek |
Cells | 2020 |
|
Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection
C Orr, W Xu, H Masur, S Kottilil, EG Meissner |
BMC Infectious Diseases | 2020 |
|
Effect of Low Positive End of Treatment Viral Load with Direct-Acting Antiviral Therapy on Sustained Virologic Response
V Pal, N Ancha, J Mann, AA Modi |
Canadian journal of gastroenterology & hepatology | 2020 |
|
Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
H Zeng, L Li, Z Hou, Y Zhang, Z Tang, S Liu |
International journal of medical sciences | 2020 |
|
The reduction of miR146b-5p in monocytes and T cells could contribute to the immunopathogenesis of hepatitis C virus infection
Y Kondo, T Kogure, M Ninomiya, R Fukuda, N Monma, K Ikeo, Y Tanaka |
Scientific Reports | 2019 |
|
Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents
M Sanduzzi-Zamparelli, L Boix, C Leal, M Reig |
Viruses | 2019 |
|
A Long Noncoding RNA Regulates Hepatitis C Virus Infection Through Interferon Alpha-Inducible Protein 6
X Liu, X Duan, JA Holmes, W Li, SH Lee, Z Tu, C Zhu, S Salloum, A Lidofsky, EA Schaefer, D Cai, S Li, H Wang, Y Huang, Y Zhao, ML Yu, Z Xu, L Chen, J Hong, W Lin, RT Chung |
Hepatology | 2019 |
|
Establishment and Characterization of a New Cell Line Permissive for Hepatitis C Virus Infection
H Omura, F Liu, T Shimakami, K Murai, T Shirasaki, J Kitabayashi, M Funaki, T Nishikawa, R Nakai, A Sumiyadorj, T Hayashi, T Yamashita, M Honda, S Kaneko |
Scientific Reports | 2019 |
|
Sofosbuvir/Ribavirin therapy for patients experiencing failure of ombitasvir/paritaprevir/ritonavir + ribavirin therapy: Two cases report and review of literature
K Sato, Y Yamazaki, T Kobayashi, S Takakusagi, N Horiguchi, S Kakizaki, M Andou, Y Matsuda, T Uraoka, H Ohnishi, H Okamoto |
World journal of clinical cases | 2019 |
|
Direct-acting antivirals and visceral leishmaniasis: a case report
C Colomba, L Saporito, PD Carlo, M Tolomeo, A Cervo, A Firenze, M Trizzino, A Cascio |
BMC Infectious Diseases | 2019 |
|
Neutrocyte-to-lymphocyte ratio predicts the presence of a replicative hepatitis C virus strand after therapy with direct-acting antivirals
A Wróblewska, B Lorenc, M Cheba, KP Bielawski, K Sikorska |
Clinical and Experimental Medicine | 2019 |
|
Individual liver plasmacytoid dendritic cells are capable of producing IFNα and multiple additional cytokines during chronic HCV infection
EH Doyle, A Rahman, C Aloman, AL Klepper, A El-Shamy, F Eng, C Rocha, S Kim, B Haydel, SS Florman, MI Fiel, T Schiano, AD Branch, G Randall |
PLoS pathogens | 2019 |
|
Direct antiviral agents for HCV infection and hepatocellular carcinoma: facts and FADs
I Serio, L Napoli, S Leoni, F Piscaglia |
Translational cancer research | 2019 |
|
Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection
B Rehermann, R Thimme |
Gastroenterology | 2018 |
|
Revisiting the Paradox of Interferon-Stimulated Gene Expression as a Predictor of Hepatitis C Virus Treatment Response, a Decade Later
L Golden-Mason, HR Rosen |
Hepatology | 2018 |
|
Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy
R Villani, G Vendemiale, G Serviddio |
International journal of molecular sciences | 2018 |
|
Interferon-free treatment for hepatitis C virus infection induces normalization of extrahepatic type I interferon signaling
PS Sung, EB Lee, DJ Park, A Lozada, JW Jang, SH Bae, JY Choi, SK Yoon |
Clinical and Molecular Hepatology | 2018 |
|
Impact of IFNL4 genotype on Interferon-stimulated Gene Expression during DAA therapy for Hepatitis C
N Ramamurthy, E Marchi, MA Ansari, V Pedergnana, A Mclean, E Hudson, R Bowden, CC Spencer, E Barnes, P Klenerman |
Hepatology | 2018 |
|
Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During DAA Therapy
H Alao, M Cam, C Keembiyehetty, F Zhang, E Serti, D Suarez, H Park, NH Fourie, EC Wright, WA Henderson, Q Li, TJ Liang, B Rehermann, MG Ghany |
Hepatology | 2018 |
|
Extrahepatic cancers and chronic HCV infection
S Pol, A Vallet-Pichard, O Hermine |
Nature Reviews Gastroenterology & Hepatology | 2018 |
|
Recurrent membranous nephropathy and acute cellular rejection in a patient treated with direct anti-HCV therapy (ledipasvir/sofosbuvir)
N Murakami, Y Ding, DJ Cohen, AK Chandraker, HG Rennke |
Transplant Infectious Disease | 2018 |
|
Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection
TJ Cory, Y Mu, Y Gong, S Kodidela, S Kumar |
Expert Opinion on Pharmacotherapy | 2018 |
|
Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group
T Mashiba, K Joko, M Kurosaki, H Ochi, Y Osaki, Y Kojima, R Nakata, T Goto, A Takehiro, H Kimura, A Mitsuda, C Kawanami, Y Uchida, C Ogawa, A Kusakabe, R Narita, Y Ide, T Abe, K Tsuji, T Kitamura, K Okada, T Sohda, M Shigeno, T Satou, N Izumi, CH Liu |
PloS one | 2018 |
|
Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study
A Kawano, H Shigematsu, K Miki, Y Ichiki, C Morita, K Yanagita, K Takahashi, K Dohmen, H Nomura, H Ishibashi, S Shimoda |
Internal Medicine | 2018 |
|
Regulation of interferon signaling and HCV‑RNA replication by extracellular matrix
T Kuwashiro, S Iwane, X Jinghe, S Matsuhashi, Y Eguchi, K Anzai, K Fujimoto, T Mizuta, N Sakamoto, M Ikeda, N Kato, I Ozaki |
International journal of molecular medicine | 2018 |
|
Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals
I Schietroma, GC Scheri, C Pinacchio, M Statzu, A Petruzziello, V Vullo |
The open virology journal | 2018 |
|
Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection
C Hayes, P Zhang, Y Zhang, K Chayama |
Viruses | 2018 |
|
Liver Angiopoietin-2 Is a Key Predictor of DeNovo or Recurrent Hepatocellular Cancer After Hepatitis CVirus Direct-Acting Antivirals
F Faillaci, L Marzi, R Critelli, F Milosa, F Schepis, E Turola, S Andreani, G Vandelli, V Bernabucci, B Lei, F D'Ambrosio, L Bristot, L Cavalletto, L Chemello, P Sighinolfi, P Manni, A Maiorana, C Caporali, M Bianchini, M Marsico, L Turco, N de Maria, MD Buono, P Todesca, L di Lena, D Romagnoli, P Magistri, F di Benedetto, S Bruno, G Taliani, G Giannelli, ML Martinez-Chantar, E Villa |
Hepatology | 2018 |
|
Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response
R Sasaki, T Kanda, N Kato, O Yokosuka, M Moriyama |
World journal of hepatology | 2018 |
|
Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin
C Orr, J Aartun, H Masur, S Kottilil, EG Meissner |
Journal of Viral Hepatitis | 2018 |
|
HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection
SO Sekyere, B Schlevogt, F Mettke, M Kabbani, K Deterding, TC Wirth, A Vogel, MP Manns, CS Falk, M Cornberg, H Wedemeyer |
Liver Cancer | 2018 |
|
Progress toward approval of an HCV vaccine.
Law JL, Logan M, Landi A, Tyrrell DL, Houghton M |
2018 | |
|
Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease
AM Gharib, MA Han, EG Meissner, DE Kleiner, X Zhao, M McLaughlin, L Matthews, B Rizvi, KZ Abd-Elmoniem, R Sinkus, E Levy, C Koh, RP Myers, GM Subramanian, S Kottilil, T Heller, JA Kovacs, CG Morse |
BioMed Research International | 2017 |
|
Designing an HCV vaccine: a unique convergence of prevention and therapy?
CM Walker |
Current Opinion in Virology | 2017 |
|
Current progress in host innate and adaptive immunity against hepatitis C virus infection
J Shi, Y Li, W Chang, X Zhang, FS Wang |
Hepatology International | 2017 |
|
Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy
MA Burchill, JA Roby, N Crochet, M Wind-Rotolo, AE Stone, MG Edwards, RJ Dran, MS Kriss, M Gale, HR Rosen, G Ahlenstiel |
PloS one | 2017 |
|
Hepatitis B reactivation during or after direct acting antiviral therapy – implication for susceptible individuals
JA Holmes, ML Yu, RT Chung |
Expert Opinion on Drug Safety | 2017 |
|
On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C
P Chu, N Nakamoto, N Taniki, K Ojiro, T Amiya, Y Makita, H Murata, A Yamaguchi, S Shiba, R Miyake, T Katayama, A Ugamura, A Ikura, K Takeda, H Ebinuma, H Saito, T Kanai, CH Liu |
PloS one | 2017 |
|
Synergistic gene expression during the acute phase response is characterized by transcription factor assisted loading
I Goldstein, V Paakinaho, S Baek, MH Sung, GL Hager |
Nature Communications | 2017 |
|
Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti-MicroRNA-122, RG-101
F Stelma, MH van der Ree, MJ Sinnige, A Brown, L Swadling, JM de Vree, SB Willemse, M van der Valk, P Grint, S Neben, P Klenerman, E Barnes, NA Kootstra, HW Reesink |
Hepatology | 2017 |
|
Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology: Clinical Pharmacology in Drug Development
CS Venuto, AH Talal |
Clinical Pharmacology in Drug Development | 2017 |
|
Immunological Predictors of Nonresponse to Directly Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Decompensated Cirrhosis
K Childs, E Merritt, A Considine, A Sanchez-Fueyo, K Agarwal, M Martinez-Llordella, I Carey |
Open Forum Infectious Diseases | 2017 |
|
Rapid changes in peripheral lymphocyte concentrations during interferon-free treatment of chronic hepatitis C virus infection
EG Meissner, A Kohli, J Higgins, YJ Lee, O Prokunina, D Wu, C Orr, H Masur, S Kottilil |
Hepatology Communications | 2017 |
|
Time course of cellular HIV-DNA and low-level HIV viremia in HIV–HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals
SG Parisi, S Andreis, M Basso, S Cavinato, R Scaggiante, M Franzetti, M Andreoni, G Palù, AM Cattelan |
Medical Microbiology and Immunology | 2017 |
|
Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C
FR Ponziani, F Mangiola, C Binda, MA Zocco, M Siciliano, A Grieco, GL Rapaccini, M Pompili, A Gasbarrini |
World journal of hepatology | 2017 |
|
Transcriptional profiling of PBMCs unravels B cell mediated immunopathogenic imprints of HCV vasculitis
E Comstock, CW Kim, A Murphy, B Emmanuel, X Zhang, M Sneller, B Poonia, S Kottilil, R Ray |
PloS one | 2017 |
|
Insulin receptor substrate-4 interacts with ubiquitin-specific protease 18 to activate the Jak/STAT signaling pathway
B Jiao, X Shi, Y Chen, H Ye, M Yao, W Hong, S Li, X Duan, Y Wang, L Chen |
Oncotarget | 2017 |
|
IFN ‐free therapy is associated with restoration of type I IFN response in HIV ‐1 patients with acute HCV infection who achieve SVR
C CarltonSmith, JA Holmes, S Naggie, A Lidofsky, GM Lauer, AY Kim, RT Chung |
Journal of Viral Hepatitis | 2017 |
|
Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk
MA Wörns, PR Galle, S Zeuzem, P Schirmacher, M Manns, A Vogel |
Deutsches Ärzteblatt international | 2017 |
|
Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing
MH van der Ree, F Stelma, SB Willemse, A Brown, L Swadling, M van der Valk, MJ Sinnige, AC van Nuenen, JM de Vree, P Klenerman, E Barnes, NA Kootstra, HW Reesink |
Antiviral Research | 2017 |
|
Chronic hepatitis C infection–induced liver fibrogenesis is associated with M2 macrophage activation
MT Bility, K Nio, F Li, DR McGivern, SM Lemon, ER Feeney, RT Chung, L Su |
Scientific Reports | 2016 |
|
Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir: Table 1
C Cooper, S Naggie, M Saag, JC Yang, LM Stamm, H Dvory-Sobol, LL Han, PS Pang, JG McHutchison, D Dieterich, M Sulkowski |
Clinical Infectious Diseases | 2016 |
|
Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial
EG Meissner, M McLaughlin, L Matthews, AM Gharib, BJ Wood, E Levy, R Sinkus, K Virtaneva, D Sturdevant, C Martens, SF Porcella, ZD Goodman, B Kanwar, RP Myers, M Subramanian, C Hadigan, H Masur, DE Kleiner, T Heller, S Kottilil, JA Kovacs, CG Morse |
Liver International | 2016 |
|
Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients
D Ji, GF Chen, C Wang, YD Wang, Q Shao, B Li, J Zhao, SL You, JH Hu, JL Liu, XX Niu, J Chen, L Lu, V Wu, G Lau |
Hepatology International | 2016 |
|
Cellular Mechanism for Impaired Hepatitis C Virus Clearance by Interferon Associated with IFNL3 Gene Polymorphisms Relates to Intrahepatic Interferon-λ Expression
P Ferraris, PK Chandra, R Panigrahi, F Aboulnasr, S Chava, R Kurt, JM Pawlotsky, L Wilkens, P Osterlund, R Hartmann, LA Balart, T Wu, S Dash |
The American Journal of Pathology | 2016 |
|
Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis
EG Meissner, A Kohli, K Virtaneva, D Sturdevant, C Martens, SF Porcella, JG McHutchison, H Masur, S Kottilil |
Journal of Viral Hepatitis | 2016 |
|
How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study
SM Tsai, JT Kao, YF Tsai |
BMC health services research | 2016 |
|
Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection
J Waldenström, J Westin, K Nyström, P Christensen, O Dalgard, M Färkkilä, K Lindahl, S Nilsson, G Norkrans, H Krarup, H Norrgren, MR Buhl, S Stenmark, M Lagging, J Grebely |
PloS one | 2016 |
|
Organ system view of the hepatic innate immunity in HCV infection: Innate Defense Program Against HCV
BR Bang, S Elmasry, T Saito |
Journal of Medical Virology | 2016 |
|
DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment
R Villani, A Facciorusso, F Bellanti, R Tamborra, A Piscazzi, M Landriscina, G Vendemiale, G Serviddio, T Kanda |
PloS one | 2016 |
|
Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer
A Samson, MJ Bentham, K Scott, G Nuovo, A Bloy, E Appleton, RA Adair, R Dave, A Peckham-Cooper, G Toogood, S Nagamori, M Coffey, R Vile, K Harrington, P Selby, F Errington-Mais, A Melcher, S Griffin |
Gut | 2016 |
|
Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients: HEPATOLOGY, Vol. XX, No. X, 2014
EG Meissner, YJ Lee, A Osinusi, Z Sims, J Qin, D Sturdevant, J McHutchison, M Subramanian, M Sampson, S Naggie, K Patel, AT Remaley, H Masur, S Kottilil |
Hepatology | 2015 |
|
Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function
E Serti, X Chepa-Lotrea, YJ Kim, M Keane, N Fryzek, TJ Liang, M Ghany, B Rehermann |
Gastroenterology | 2015 |
|
Natural Killer Cells in Viral Hepatitis
B Rehermann |
CMGH Cellular and Molecular Gastroenterology and Hepatology | 2015 |
|
Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy
EG Meissner, J Decalf, A Casrouge, H Masur, S Kottilil, ML Albert, D Duffy, SJ Polyak |
PloS one | 2015 |
|
IFN-λ Inhibits MiR-122 Transcription through a Stat3-HNF4α Inflammatory Feedback Loop in an IFN-α Resistant HCV Cell Culture System
F Aboulnasr, S Hazari, S Nayak, PK Chandra, R Panigrahi, P Ferraris, S Chava, R Kurt, K Song, A Dash, LA Balart, RF Garry, T Wu, S Dash, G Ahlenstiel |
PloS one | 2015 |
|
Utility of Hepatitis C Viral Load Monitoring on Direct-Acting Antiviral Therapy
S Sidharthan, A Kohli, Z Sims, A Nelson, A Osinusi, H Masur, S Kottilil |
Clinical Infectious Diseases | 2015 |
|
Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype–genotype correlation study
M Noureddin, Y Rotman, F Zhang, H Park, B Rehermann, E Thomas, TJ Liang |
Genes and Immunity | 2015 |
|
Expression of Interferon Lambda 4 Is Associated with Reduced Proliferation and Increased Cell Death in Human Hepatic Cells
OO Onabajo, P Porter-Gill, A Paquin, N Rao, L Liu, W Tang, N Brand, L Prokunina-Olsson |
Journal of Interferon & Cytokine Research | 2015 |
|
Differential Specificity of Interferon-alpha Inducible Gene Expression in Association with Human Immunodeficiency Virus and Hepatitis C Virus Levels and Declines in vivo
A Katsounas |
Journal of AIDS & Clinical Research | 2015 |
|
Ribavirin Contributes to Hepatitis C Virus Suppression by Augmenting pDC Activation and Type 1 IFN Production
Y Wang, DR McGivern, L Cheng, G Li, SM Lemon, J Niu, L Su, NJ Reszka-Blanco, W Ho |
PloS one | 2015 |
|
Comparison of Functional Variants in IFNL4 and IFNL3 for Association with Hepatitis C Virus Clearance
TR OBrien, RM Pfeiffer, A Paquin, KA Kuhs, S Chen, HL Bonkovsky, BR Edlin, CD Howell, GD Kirk, MH Kuniholm, TR Morgan, HD Strickler, DL Thomas, L Prokunina-Olsson |
Journal of Hepatology | 2015 |
|
Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy
S Nakamoto, F Imazeki, M Arai, S Yasui, M Nakamura, Y Haga, R Sasaki, T Kanda, H Shirasawa, O Yokosuka |
International journal of molecular sciences | 2015 |
|
Activation of Type I and Type III Interferons in Chronic Hepatitis C
S Mihm |
Journal of Innate Immunity | 2015 |
|
Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use
G Antonelli, C Scagnolari, F Moschella, E Proietti |
Cytokine & Growth Factor Reviews | 2014 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)